


下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemESC66Cat. No.: HY-19832CAS No.: 871361-88-5分式: CHNO分量: 276.33作靶點(diǎn): Akt; Apoptosis作通路: PI3K/Akt/mTOR; Apoptosis儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 34 mg/mL (123.04 mM)* means solub
2、le, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 3.6189 mL 18.0943 mL 36.1886 mL5 mM 0.7238 mL 3.6189 mL 7.2377 mL10 mM 0.3619 mL 1.8094 mL 3.6189 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 SC66種 Akt 抑制劑,降低細(xì)胞活,這種作存在劑量和時(shí)間依賴性,且抑制肝癌 (HCC) 細(xì)胞的集落形成和誘
3、導(dǎo)凋亡。IC50 & Target Akt體外研究SC66 inhibits cell viability and colony forming capacity of HCC cells with IC50s of 0.77,0.47,0.92,0.751/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEand 2.85 g/mL at 72 hours for HepG2, Hep3B, PLC/PRF/5,HA22T/VGH and Huh7 cells. HepG2,HA22T/VGH and PLC/PRF/5 cells have si
4、milar IC50s of approximately 0.85 and 0.75 g/mL at 48 and 72hours, respectively. To determine whether the decrease in cell viability is related to apoptosis induction,TUNEL assays are performed in Hep3B and Huh7 cells treated with 1, 2 and 4 g/mL of SC66 for 24 hours.In Hep3B cells the number of TUN
5、EL-positive cells increased with increasing concentrations of SC66,whereas in Huh7 cells very few light brown-colored cells are observed only after treatment with 4 g/mLSC66 1.體內(nèi)研究 To demonstrate the effectiveness in vivo of SC66 on HCC, a mouse xenograft tumor model of Hep3B cells isused. When tumo
6、rs became palpable, at a size of about 150 mm3, mice are randomized into three groups of6 animals each. The treated group receive SC66 at 15 and 25 mg/kg twice a week via i.p. injection, while theuntreated group receive the vehicle alone. Treatment with 25 mg/Kg SC66 significantly reduces tumorvolum
7、e to 37% on day 17 when compared with tumors of the untreated group 1.PROTOCOLCell Assay 1 Cells (5 103/well) are distributed into each well of 96-well microtiter plates and then incubated overnight. Attime 0, the medium is replaced with fresh complete medium and different doses of SC66 are added. C
8、ells arecultured for 24, 48 and 72 hours. At the end of treatment, MTS assays are performed using the CellTiterAqueous OneSolution kit. Cell viability is expressed as a percentage of the absorbance measured in thecontrol cells. Values are expressed as meansSD of three separate experiments, each perf
9、ormed in triplicate1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 1Administration 1 Male nude athymic mice (Fox1 nu/nu) aged 4 weeks are used. Suspensions of 1107 Hep3B cells in 0.2 mLof PBS are inoculated into the right flank of the anim
10、al. When tumors became palpable (around 150 mm3),the mice are randomly divided into three groups of 6 animals each, with the various tumor volumes equallydistributed among the three groups. Two groups of mice are treated twice a week with 15 and 25 mg/kgSC66 suspended in DMSO, further diluted in a s
11、olution of 25% ethanol and administered via i.p. injection.The control group receive the vehicle alone. Tumor volumes are determined twice a week using calipers.Primary tumor volumes are calculated.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Cusimano A, et al. Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells. Oncotarget. 2015Jan 30;6(3):1707-22.McePdfHeightCaution: Product
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年中國新型顯示器件行業(yè)發(fā)展全景監(jiān)測及投資方向研究報(bào)告
- 城中村改造項(xiàng)目配套基礎(chǔ)設(shè)施建設(shè)項(xiàng)目可行性研究報(bào)告
- 呼和浩特化妝鏡項(xiàng)目投資分析報(bào)告模板范本
- 2025年中國停車場行業(yè)發(fā)展前景預(yù)測及投資戰(zhàn)略研究報(bào)告
- 中國清管器行業(yè)市場深度分析及投資策略研究報(bào)告
- 2025-2030齒輪鋼項(xiàng)目可行性研究報(bào)告
- 2025-2030鵝去氧膽酸行業(yè)市場現(xiàn)狀供需分析及投資評估規(guī)劃分析研究報(bào)告
- 2025-2030高端紅酒行業(yè)市場深度分析及發(fā)展策略研究報(bào)告
- 2025-2030高強(qiáng)度聚焦超聲系統(tǒng)行業(yè)市場現(xiàn)狀供需分析及投資評估規(guī)劃分析研究報(bào)告
- 2025-2030骨水泥市場發(fā)展現(xiàn)狀調(diào)查及供需格局分析預(yù)測研究報(bào)告
- 2024【小學(xué)組】漢字聽寫大會(huì)競賽考試題庫(含答案)
- 新高考背景下高考數(shù)學(xué)重點(diǎn)板塊分析與教學(xué)建議課件
- 課件分享-中考成長類作文寫作指導(dǎo)
- 22《桃花源記》對比閱讀-2024-2025中考語文文言文閱讀專項(xiàng)訓(xùn)練(含答案)
- 《火針療法》課件
- 銀行柜面崗位資格操作技能等級考試題(附答案)
- JT-T-891-2014道路車輛清障救援操作規(guī)范
- 上海滬教牛津版小學(xué)五年級英語下冊Unit 1 Tidy up!習(xí)題及答案
- 養(yǎng)殖水質(zhì)硫化氫的檢測
- 【公文基礎(chǔ)】公文寫作培訓(xùn)公文寫作格式以及要點(diǎn)
- 第24屆世界奧林匹克數(shù)學(xué)競賽WMO省級測評三年級試卷【含答案】
評論
0/150
提交評論